Amendment history : Corrigendum ( April 2005 ) Liver fibrosis Ramón Bataller

Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Our knowledge of the cellular and molecular mechanisms of liver fibrosis has greatly advanced. Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver. These cells are activated by fibrogenic cytokines such as TGF-beta1, angiotensin II, and leptin. Reversibility of advanced liver fibrosis in patients has been recently documented, which has stimulated researchers to develop antifibrotic drugs. Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins. Although many therapeutic interventions are effective in experimental models of liver fibrosis, their efficacy and safety in humans is unknown. This review summarizes recent progress in the study of the pathogenesis and diagnosis of liver fibrosis and discusses current antifibrotic strategies.

[1]  F. Klion,et al.  Chronic hepatitis. , 1968, Annual review of medicine.

[2]  H. Popper,et al.  Hepatic fibrosis. Correlation of biochemical and morphologic investigations. , 1970, The American journal of medicine.

[3]  J. Aldrete,et al.  Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. , 1976, Surgery.

[4]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[5]  Isolation of a lipocyte-rich fraction from rat liver nonparenchymal cells. , 1980, Advances in experimental medicine and biology.

[6]  S. Friedman,et al.  Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Caballería,et al.  Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. , 1986, Journal of hepatology.

[8]  L. Gesualdo,et al.  Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. , 1989, The Journal of clinical investigation.

[9]  H. Stein,et al.  Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. , 1990, Gastroenterology.

[10]  S. Friedman,et al.  Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. , 1992, Journal of submicroscopic cytology and pathology.

[11]  S. Friedman,et al.  Isolated hepatic lipocytes and kupffer cells from normal human liver: Morphological and functional characteristics in primary culture , 1992, Hepatology.

[12]  J. Maher,et al.  Acetaldehyde-induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture: studies with rat lipocytes and fibroblasts. , 1994, Alcoholism, clinical and experimental research.

[13]  D. Rockey,et al.  Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Foschi,et al.  Neutrophil‐derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: Role of nitric oxide , 1997, Hepatology.

[15]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[16]  R. Thurman,et al.  II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[17]  S. Wasser,et al.  Experimental models of hepatic fibrosis in the rat. , 1999, Annals of the Academy of Medicine, Singapore.

[18]  M. Zago,et al.  Are Haemochromatosis Mutations Related to the Severity of Liver Disease in Hepatitis C Virus Infection? , 1999, Acta Haematologica.

[19]  F. Marra,et al.  Extracellular signal‐regulated kinase activation differentially regulates platelet‐derived growth factor's actions in hepatic stellate cells, and is induced by In Vivo liver injury in the rat , 1999, Hepatology.

[20]  F. Piscaglia,et al.  Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. , 1999, Gastroenterology.

[21]  P. Thampanitchawong,et al.  Liver biopsy:complications and risk factors. , 1999, World journal of gastroenterology.

[22]  F. Marra.  Hepatic stellate cells and the regulation of liver inflammation. , 1999, Journal of hepatology.

[23]  D. Brenner,et al.  NF-kappaB inhibits expression of the alpha1(I) collagen gene. , 1999, DNA and cell biology.

[24]  Y. Watanabe,et al.  Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. , 2000, Scandinavian journal of gastroenterology.

[25]  M. Arthur.  Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[26]  B. Stefanovic,et al.  Fibrogenesis. III. Posttranscriptional regulation of type I collagen. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[27]  P. Bedossa,et al.  Natural history of HCV infection. , 2000, Bailliere's best practice & research. Clinical gastroenterology.

[28]  D. Schuppan,et al.  An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. , 2000, Gastroenterology.

[29]  Ji-lin Cheng,et al.  Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). , 2000, World journal of gastroenterology.

[30]  Ji-lin Cheng,et al.  The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis:effects of RAS inhibitors on hepatic fibrosis induced by CCl(4). , 2000, World journal of gastroenterology.

[31]  R. Bataller,et al.  Angiotensin II induces contraction and proliferation of human hepatic stellate cells. , 2000, Gastroenterology.

[32]  R. Caporale,et al.  Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. , 2000, Gastroenterology.

[33]  D. Purdie,et al.  Host genetic factors influence disease progression in chronic hepatitis C , 2000, Hepatology.

[34]  I. Rusyn,et al.  NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. , 2000, The Journal of clinical investigation.

[35]  J. Iredale,et al.  Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo , 2001, Gut.

[36]  D. Agarwal.  Genetic polymorphisms of alcohol metabolizing enzymes. , 2001, Pathologie-biologie.

[37]  S. Friedman,et al.  Hepatic fibrosis. Pathogenesis and principles of therapy , 2001 .

[38]  S. Friedman,et al.  DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. , 2001, The Journal of clinical investigation.

[39]  O. Chazouilleres,et al.  Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? , 2001, Journal of hepatology.

[40]  D. Valla,et al.  Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. , 2001, The New England journal of medicine.

[41]  Z. Kmieć,et al.  Cooperation of Liver Cells in Health and Disease , 2001, Advances in Anatomy Embryology and Cell Biology.

[42]  K. Chayama,et al.  Risk factors of hepatitis C virus‐related liver cirrhosis in young adults: Positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) *0201 Allele , 2001, Journal of medical virology.

[43]  D. Brenner,et al.  The role of Smad3 in mediating mouse hepatic stellate cell activation , 2001, Hepatology.

[44]  M. Kaplan,et al.  Is liver fibrosis reversible? , 2001, The New England journal of medicine.

[45]  T. Poynard,et al.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study , 2001, The Lancet.

[46]  R. Schwabe,et al.  CD40 Activates NF-κB and c-Jun N-Terminal Kinase and Enhances Chemokine Secretion on Activated Human Hepatic Stellate Cells1 , 2001, The Journal of Immunology.

[47]  A Geerts,et al.  History, Heterogeneity, Developmental Biology, and Functions of Quiescent Hepatic Stellate Cells , 2001, Seminars in liver disease.

[48]  I. Rusyn,et al.  The role of Kupffer cell oxidant production in early ethanol-induced liver disease. , 2001, Free radical biology & medicine.

[49]  D. Pessayre,et al.  Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. , 2001, Gastroenterology.

[50]  D. Brenner,et al.  Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis , 2001, Seminars in liver disease.

[51]  J. Maher.  Interactions between Hepatic Stellate Cells and the Immune System , 2001, Seminars in liver disease.

[52]  Y Ando,et al.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. , 2001, Gastroenterology.

[53]  P. Boya,et al.  Nuclear factor‐κB in the liver of patients with chronic hepatitis C: Decreased RelA expression is associated with enhanced fibrosis progression , 2001, Hepatology.

[54]  N. Horiike,et al.  Noninvasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus , 2001, European journal of clinical investigation.

[55]  M. Perola,et al.  Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease , 2001, Hepatology.

[56]  P. Donaldson,et al.  HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility , 2001, Gut.

[57]  P. Angus,et al.  Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. , 2001, Journal of hepatology.

[58]  H. Yoshiji,et al.  Tissue inhibitor of metalloproteinases‐1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse , 2002, Hepatology.

[59]  F. Marra.  Leptin and liver fibrosis: a matter of fat. , 2002, Gastroenterology.

[60]  S. Dooley,et al.  Roles of TGF-beta in hepatic fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[61]  F. Ramalho,et al.  Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. , 2002, Hepato-gastroenterology.

[62]  C. Housset,et al.  Peribiliary myofibroblasts in biliary type liver fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[63]  G. Gores,et al.  Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. , 2002, Gastroenterology.

[64]  M. Berenguer,et al.  Contribution of obesity to hepatitis C-related fibrosis progression , 2002, American Journal of Gastroenterology.

[65]  E. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[66]  Llorenç Quintó,et al.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.

[67]  P. Angus,et al.  Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. , 2002, Gastroenterology.

[68]  PDGF and signal transduction in hepatic stellate cells. , 2002 .

[69]  M. Arthur,et al.  Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. , 2002, Gastroenterology.

[70]  R. Fontana,et al.  Noninvasive monitoring of patients with chronic hepatitis C , 2002, Hepatology.

[71]  Y. Takei,et al.  Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. , 2002, Gastroenterology.

[72]  D. Mann,et al.  Transcriptional regulation of hepatic stellate cell activation , 2002, Gut.

[73]  D. Crabb,et al.  Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. , 2002, Gastroenterology.

[74]  F. Marra,et al.  Chemokines in liver inflammation and fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[75]  Mitsuru Sato,et al.  Hepatic stellate cells: unique characteristics in cell biology and phenotype. , 2003, Cell structure and function.

[76]  S. Dooley,et al.  Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. , 2003, Gastroenterology.

[77]  A. Diehl,et al.  Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells. , 2003, Biochemical and biophysical research communications.

[78]  Takashi Yamamoto,et al.  SERIES : Hepatic sinusoidal cells in liver physiology and pathology , 2004 .

[79]  H. Bujard,et al.  Conditional tetracycline‐regulated expression of TGF‐β1 in liver of transgenic mice leads to reversible intermediary fibrosis , 2003, Hepatology.

[80]  K. Chayama,et al.  AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). , 2003, Biochemical and biophysical research communications.

[81]  G. Gores,et al.  Mechanisms of liver injury: an overview. , 2003, Current molecular medicine.

[82]  W. Mckeehan,et al.  Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. , 2003, The American journal of pathology.

[83]  G. Gores,et al.  Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. , 2003, The Journal of clinical investigation.

[84]  R. Kalluri,et al.  Epithelial-mesenchymal transition and its implications for fibrosis. , 2003, The Journal of clinical investigation.

[85]  D. Brenner,et al.  Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal , 2003, Hepatology.

[86]  Christian Jobin,et al.  Toll‐Like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells , 2003, Hepatology.

[87]  R. Bataller,et al.  Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. , 2003, Gastroenterology.

[88]  D. Brenner,et al.  Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[89]  S. Kihara,et al.  Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. , 2003, Gastroenterology.

[90]  R. Bataller,et al.  Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. , 2003, Hepatology.

[91]  R. Schwabe,et al.  NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. , 2003, The Journal of clinical investigation.

[92]  D. Brenner,et al.  Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. , 2003, Frontiers in bioscience : a journal and virtual library.

[93]  J. Mir,et al.  Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus–related graft cirrhosis , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[94]  G. Davis,et al.  Projecting future complications of chronic hepatitis C in the United States , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[95]  S. Friedman,et al.  Liver fibrosis -- from bench to bedside. , 2003, Journal of hepatology.

[96]  S. Uğraş,et al.  Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. , 2003, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[97]  Ramon Bataller,et al.  Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[98]  D. Schuppan,et al.  Hepatitis C and liver fibrosis , 2003, Cell Death and Differentiation.

[99]  G. Gores,et al.  Apoptosis: The nexus of liver injury and fibrosis , 2004, Hepatology.

[100]  V. Arroyo,et al.  Management of cirrhosis and ascites. , 2004, The New England journal of medicine.

[101]  Takahiro Suzuki,et al.  Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. , 2004, Gastroenterology.

[102]  N. Afdhal,et al.  Evaluation of Liver Fibrosis: A Concise Review , 2004, American Journal of Gastroenterology.

[103]  J. Dixon,et al.  Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss , 2004, Hepatology.

[104]  R. Green,et al.  Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[105]  D. Brenner,et al.  Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. , 2004, Gastroenterology.

[106]  R. Contreras,et al.  Noninvasive diagnosis of liver cirrhosis using DNA sequencer–based total serum protein glycomics , 2004, Nature Medicine.

[107]  C. Day.  The potential role of genes in nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[108]  D. Suskind,et al.  Searching for common stem cells of the hepatic and hematopoietic systems in the human fetal liver: CD34+ cytokeratin 7/8+ cells express markers for stellate cells. , 2004, Journal of hepatology.

[109]  S. Friedman,et al.  Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. , 2004, Gastroenterology.

[110]  G. Ramadori,et al.  Portal tract fibrogenesis in the liver , 2004, Laboratory Investigation.

[111]  I. Wanless,et al.  The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. , 2004, Seminars in liver disease.

[112]  E. Brunt.  Nonalcoholic steatohepatitis. , 2004, Seminars in liver disease.

[113]  M. Burdick,et al.  Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. , 2004, The Journal of clinical investigation.

[114]  Christopher J. Parsons,et al.  Regulation of alpha1(I) collagen messenger RNA decay by interactions with alphaCP at the 3'-untranslated region. , 2004, The Journal of biological chemistry.

[115]  F. Shek,et al.  How can transforming growth factor beta be targeted usefully to combat liver fibrosis? , 2004, European journal of gastroenterology & hepatology.

[116]  Takafumi Yoshida,et al.  SOCS1 Is a Suppressor of Liver Fibrosis and Hepatitis-induced Carcinogenesis , 2004, The Journal of experimental medicine.

[117]  N. Sinelli,et al.  Hepatic fibrogenesis requires sympathetic neurotransmitters , 2004, Gut.

[118]  M. Rugge,et al.  A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. , 2004, Gastroenterology.

[119]  M. Pinzani.  Liver fibrosis , 2004, Springer Seminars in Immunopathology.

[120]  J. Fallowfield,et al.  Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. , 2004, Gastroenterology.

[121]  R. Schwabe,et al.  Differential requirement for c‐Jun NH2‐terminal kinase in TNF‐α‐and Fas‐mediated apoptosis in hepatocytes , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[122]  A. Gressner,et al.  Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. , 2004, Biochemical and biophysical research communications.

[123]  D. Brenner,et al.  A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations , 2004, Hepatology.